Colorectal Cancer Is Getting Younger: Why Screening at 45 Matters and Where Medical Cannabis Fits in Care
March is Colorectal Cancer Awareness Month — an opportunity to highlight both progress and concern in colorectal cancer (CRC) prevention and management.
One of the most notable and troubling trends in recent years has been the rise in colorectal cancer diagnoses among individuals under the age of 50. This epidemiologic shift has prompted significant changes in screening recommendations and raises important questions regarding risk factors, prevention strategies, and supportive care approaches.
The Rise of Early-Onset Colorectal Cancer
Colorectal cancer remains one of the most common and deadly malignancies worldwide¹. Historically considered a disease of older adults, CRC is increasingly being diagnosed in individuals in their 30s and 40s.
The reasons for this trend are likely multifactorial.
Lifestyle-associated risk factors — including obesity, sedentary behavior, increased consumption of processed and red meats, alcohol use, tobacco exposure, and dietary shifts toward ultra-processed foods — have been associated with colorectal carcinogenesis¹. Chronic inflammation is also recognized as a critical contributor. Inflammatory bowel disease, for example, confers a significantly elevated risk of colorectal cancer¹.
Beyond discrete inflammatory disorders, growing attention is being directed toward systemic metabolic dysfunction, microbiome alterations, and low-grade chronic inflammation as potential drivers of earlier tumor development.
Colorectal cancer typically evolves through the adenoma–carcinoma sequence, a gradual transformation of benign polyps into invasive malignancy over years¹. If carcinogenic exposures and inflammatory influences begin earlier in life, earlier malignant transformation is biologically plausible.
While hereditary syndromes such as Lynch syndrome and familial adenomatous polyposis remain important contributors in select populations¹, the majority of colorectal cancers are sporadic¹, reinforcing the importance of environmental and modifiable risk factors.
Why Screening Now Begins at Age 45
In response to rising incidence in younger populations, major medical societies now recommend that average-risk individuals initiate colorectal cancer screening at age 45.
Early-stage colorectal cancer carries a 5-year survival rate approaching 90%¹. In contrast, survival declines dramatically in metastatic disease.
Screening is therefore both diagnostic and preventative. Colonoscopy enables detection and removal of precancerous adenomas before malignant transformation occurs.
The reduction of the screening age represents a critical public health adjustment to evolving epidemiology.
Standard Treatment Paradigms in Colorectal Cancer
Management of colorectal cancer is determined by stage, molecular subtype, and patient-specific factors.
- Surgery remains the cornerstone of treatment for localized disease.
- Chemotherapy regimens frequently include fluoropyrimidines, oxaliplatin, and irinotecan-based combinations¹.
- Immunotherapy has demonstrated meaningful benefit in select molecular subtypes, particularly mismatch repair–deficient tumors¹.
While these therapies can be life-prolonging and potentially curative, they are often accompanied by significant symptom burden, including nausea, vomiting, neuropathy, fatigue, pain, and psychological distress.
This symptom burden underscores the importance of evidence-based supportive care strategies.
The Evidence-Based Role of Medical Cannabis in Colorectal Cancer Care
Medical cannabis should not be considered a treatment for CRC – it is not a substitute for surgery, chemotherapy, radiation, or immunotherapy.
However, cannabinoids may serve a meaningful adjunctive role in symptom management when integrated thoughtfully into comprehensive cancer care.
Cannabinoids act on the endocannabinoid system, which plays a regulatory role in inflammation, immune signaling, pain modulation, and homeostasis¹. CB1 receptors are primarily located within the central nervous system, while CB2 receptors are predominantly expressed in immune cells².
The following areas represent the most evidence-supported applications in oncology supportive care.
Chemotherapy-Induced Nausea and Vomiting
Synthetic delta-9-tetrahydrocannabinol (THC) preparations (dronabinol and nabilone) are FDA-approved for chemotherapy-induced nausea and vomiting refractory to conventional antiemetics².
Controlled clinical trials have demonstrated efficacy comparable to older antiemetic agents, with some patients expressing preference for cannabinoid-based therapies².
Cannabinoids may therefore represent a valuable adjunct option for patients with persistent symptoms.
Cancer-Related Pain
Cannabinoids exert analgesic effects through central CB1-mediated mechanisms and peripheral CB2-mediated pathways².
Clinical investigations have demonstrated that THC can produce analgesia comparable to moderate doses of codeine in cancer pain². Additionally, preclinical and limited clinical data suggest potential synergistic interaction with opioids², raising the possibility of dose-sparing effects.
Further high-quality trials are warranted; however, cannabinoids present a safer option than opioids for the treatment of mild to moderate pain, and may be used in conjunction with opioids, often at lower doses of opioids.
Anxiety, Depression, and Sleep Disturbance
A cancer diagnosis frequently precipitates psychological distress and insomnia.
Cannabinoids have demonstrated anxiolytic and sedative effects in some patients². While psychoactive effects must be carefully managed and patient selection is essential, certain individuals report meaningful improvements in sleep quality and anxiety symptoms.
Addressing psychological well-being is an integral component of comprehensive oncology care.
Antitumor Potential: Current Evidence and Limitations
Preclinical studies suggest that cannabinoids may inhibit proliferation, induce apoptosis, and suppress angiogenesis in colorectal cancer models¹.
However, these findings are derived primarily from in vitro and animal studies. Robust human clinical evidence demonstrating tumor regression or survival benefit remains insufficient².
It is therefore essential to clearly communicate that cannabis should not replace evidence-based oncologic therapies. Claims of cannabis as a curative intervention for colorectal cancer are not supported by current clinical data.
Integrating Cannabis Responsibly in Oncology Care
Emerging literature suggests that cannabinoids may modulate inflammatory pathways¹ and improve appetite, nausea, pain, and sleep².
When considered, cannabinoid therapy should be:
- Adjunctive
- Evidence-informed
- Individualized
- Monitored within a structured clinical framework
The mission of the Association of Cannabinoid Specialists is to advance cannabinoid medicine through rigorous science, clinical responsibility, and patient-centered care.
A Public Health Imperative
The most powerful intervention against colorectal cancer remains prevention and early detection.
Individuals aged 45 and older should undergo appropriate screening. Patients with concerning symptoms — rectal bleeding, unexplained anemia, persistent changes in bowel habits, abdominal pain — should seek prompt evaluation.
Colorectal cancer awareness must translate into measurable action:
- Earlier screening
- Evidence-based treatment
- Responsible integration of supportive therapies
- Ongoing scientific investigation into cannabinoid medicine
Science, integrity, and patient safety must remain the guiding principles.
References
- Zaiachuk M, Pryimak N, Kovalchuk O, Kovalchuk I. Cannabinoids, Medical Cannabis, and Colorectal Cancer Immunotherapy. Front Med. 2021;8:713153. doi:10.3389/fmed.2021.713153
https://www.frontiersin.org/articles/10.3389/fmed.2021.713153/full - Abrams DI, Guzman M. Cannabis in Cancer Care. Clin Pharmacol Ther. 2015;97(6):575–586. doi:10.1002/cpt.108
https://escholarship.org/uc/item/6367m6vj